



Review

Immunoregulatory Property of C-Type Lectin-Like Receptors in Fibrosing Interstitial Lung Diseases

Wiwin Is Effendi ^{1,2}, Tatsuya Nagano ^{1,*} , Helmia Hasan ² and Resti Yudhawati ²

¹ Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan; wisepulmo@gmail.com

² Department of Pulmonology and Respiratory Medicine, Medical Faculty of Airlangga University, Surabaya 60131, Indonesia; el_helmia@yahoo.com (H.H.); restiyudhawati@gmail.com (R.Y.)

* Correspondence: tnagano@med.kobe-u.ac.jp; Tel.: +81-78-382-5660; Fax: +81-78-382-5661

Received: 4 May 2020; Accepted: 21 May 2020; Published: 22 May 2020



Abstract: The innate immune system identifies exogenous threats or endogenous stress through germline-encoded receptors called pattern recognition receptors (PRRs) that initiate consecutive downstream signaling pathways to control immune responses. However, the contribution of the immune system and inflammation to fibrosing interstitial lung diseases (ILD) remains poorly understood. Immunoreceptor tyrosine-based motif-bearing C-type lectin-like receptors (CTLRs) may interact with various immune cells during tissue injury and wound repair processes. Dectin-1 is a CTLR with dominant mechanisms manifested through its intracellular signaling cascades, which regulate fibrosis-promoting properties through gene transcription and cytokine activation. Additionally, immune impairment in ILD facilitates microbiome colonization; hence, Dectin-1 is the master protector in host pulmonary defense against fungal invasion. Recent progress in determining the signaling pathways that control the balance of fibrosis has implicated immunoreceptor tyrosine-based motif-bearing CTLRs as being involved, either directly or indirectly, in the pathogenesis of fibrosing ILD.

Keywords: innate immunity; pattern recognition receptors; C-type lectin-like receptors; immunoregulatory receptor; tyrosine-based signaling motifs; interstitial lung diseases

1. Introduction

Innate and adaptive immunity liaise with each other for defending the human body. The innate immune system is an evolutionarily conserved host defense system that encompasses virtually all tissues and may be triggered through germline-encoded receptors, including PRRs that are expressed both on immune and nonimmune cells [1]. These receptors recognize specific molecules known as pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), activating consecutive proinflammatory responses to eliminate infectious agents [2]. PRRs are divided into four significant subfamilies: Toll-like receptors (TLRs), nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), retinoic acid-inducible gene-1 (RIG-1)-like receptors (RLRs), and C-type lectin receptors (CLRs) [3].

CLRs constitute a superfamily of transmembrane proteins and soluble receptors that Ca²⁺-dependent carbohydrate-recognition domains (CRDs) recognize as self (endogenous) or nonself (exogenous) ligands [4]. Nevertheless, some CLRs, known as CTLRs, are also associated with CRDs and are not restricted to interacting with carbohydrates, such as β -glucan, binding many noncarbohydrate ligands, such as lipids and proteins [5]. CTLRs expressed by myeloid and nonmyeloid cells regulate intracellular signaling networks of the immune system and regulators of homeostasis via tyrosine-based signaling motifs [6]. A recent study showed that one cluster of the CTLR family, dendritic cell-associated

C-type lectin-1 (Dectin-1), regulates fibrosis through macrophage colony-stimulating factor (M-CSF) expression [7]. In the balancing mechanism of fibrosis, CTLRs might be expressed in the initial phase of tissue injury and wound repair of the fibrosis process [8].

The mechanisms of immunoregulation are based on the recognition systems of antigen specificity and the interconnecting systems of innate immunity at different levels and manifest in various ways [9]. At the cellular level, Treg cells are essential for establishing and maintaining immunological self-tolerance and downregulating various immune responses to antigens of pathogens [10].

Intermolecular biochemical signaling events based on tyrosine phosphorylation are essential in balancing activating and inhibitory immune responses to microorganisms [11]. Immunoreceptor tyrosine-based activation motif (ITAM)- and immunoreceptor tyrosine-based inhibition motif (ITIM)-mediated signal transduction responses are needed for degranulation, phagocytosis, cell-mediated cytotoxicity, and the production of cytokines or various antimicrobial molecular species [12].

The interplay of signals transduced directly via tyrosine-based signaling motifs or indirectly via association with transmembrane adaptor proteins (TRAPs) demonstrates the plasticity and versatility of innate immunity [13]. In general, there are seven TRAPs, including linker for activation of T cells (LAT), protein-associated with GEMs (PAG)/carboxy (C)-terminal Src kinase (CSK)-binding protein (CBP), non-T-cell activation linker (NTAL)/linker for activation of B cells (LAB), LCK-interacting membrane protein (LIME), TCR-interacting molecule (TRIM), SH2-domain-containing protein tyrosine phosphatase (SHP2)-interacting TRAP (SIT) and linker for activation of X cells (LAX, where X denotes an unidentified cell) [14].

Focusing on tyrosine-based signaling motifs, in this review, we describe some CTLR families (Dectin-1 and MICAL), discussing recent discoveries of their involvement in lung fibrotic mechanisms and their prospects as potential targets in ILD.

2. C-Type Lectin-Like Receptors

The characteristics of CTLRs are achieved when the second loop of normal CLRs (the extended loop region), which are Ca^{2+} -dependent carbohydrates for binding ligands, is cleaved [15]. Myeloid CTLRs are essential molecules involved in a wide variety of cellular functions, such as inflammatory responses, endocytosis, phagocytosis, and cytokine production [16]. Indeed, in addition to serving as antigen-uptake receptors for internalization and presentation to T cells, CTLRs also trigger multiple signaling pathways that result in the activation of nucleus factor- $\kappa\beta$ (NF- $\kappa\beta$), type I interferon (IFN), and/or inflammasomes, and mitogen-activating protein kinases (MAPK) [17,18].

Myeloid CTLRs, based on cytoplasmic signaling networks, can be divided into three leading groups: ITAM-bearing CTLRs, ITIM-bearing CTLRs, and non-immunoreceptor tyrosine-based motif-bearing CTLRs [18]. The signaling families of myeloid CTLRs are described in Figure 1.

2.1. ITAM- and HemITAM-Bearing CTLRs

The structure of complex immunoregulatory receptors consists of (1) the interface domain for target recognition at the cell surface and communication of extracellular stimuli to sophisticated intracellular signaling networks via (2) transmembrane (TM) segments and (3) cytoplasmic tail (CYT) regions of varying length [12]. The TM protein connects with at least one extracellular interface domain and one or more ITAMs within the CYT [19].

The classical motifs of ITAM are characterized by two intracellular YxxL/I sequences separated by 6 to 12 amino acids (YxxL/Ix(6-12)YxxL/I), where x represents any amino acid [20]. Initially, the ITAM was recognized only as a sequence in the CYT but was later found to be present in both the CYT of receptors and TRAPs, where it serves as a critical link to downstream signaling cascades [21].

The activation of ITAM-bearing CTLRs is associated with Syk or Zap-70, either directly as an integral component of a single ITAM-containing CYT (Dectin-1, CLEC-2, DNGR-1, and SIGN-R3) or with signaling TRAPs connected to classic ITAM motifs, such as the Fc receptor γ -chain (FcR γ) or

DAP10/DAP12 (Dectin-2, hBDCA-2, mDCAR, mDCAR1, Mincle, and MDL-1) [22]. Upon activation, most CTLRs mediate intracellular signaling pathways associated with ITAM-bearing TRAPs [23].




Figure 1. Schematic representation of myeloid CTLRs based on cytoplasmic signaling networks and the binding of early adaptors. (a) hemITAM-bearing CTLRs transduce signals via Syk through a single tyrosine-based motif in their tail; Dectin-1. (b) ITAM-bearing CTLRs transduce signals via Syk through association with ITAM-bearing adaptors such as FcR γ chain or DAP-12; Dectin-2. (c) ITIM-bearing CTLRs possess an ITIM motif; M1CL.

Dectin-1 (CLEC7A, CLECSF12, CANDF4, CD369, and BGR) is one of the most intensively studied CTLRs with many of its characteristics well defined. Dectin-1 is a 28-KDa PRR that binds β -glucans via β -1,3 or both β -1,3 and β -1,6 glycosidic bonds [24] and an endogenous undefined ligand on T cells [25]. Dectin-1 is predominantly expressed on the surface of alveolar macrophages [26]. Human Dectin-1 has only N-linked glycosylation sites in the stalk region; however, N-linked glycosylation of Dectin-1 is essential for its recognition of fungal β -glucan and the subsequent activation of NF- κ B [27]. The “phagocytic synapse” mode allows Dectin-1-binding β -glucans on the cell wall of pathogens and soluble β -glucans, excluding the clustered receptors in tyrosine phosphatases CD45 and CD148, which are activated by particulate β -glucans [28]. These synapses ensure that phagocytosis and the production of reactive oxygen species (ROS) occur only when an invading microorganism is physically close [29].

β -glucans are natural polysaccharides produced by bacteria, yeast, fungi, and many plants. The innate immune system recognizes β -glucans in their various forms and translates recognition into intracellular signaling, stimulates cellular responses, and participates in orchestrating the adaptive immune response [30]. β -glucans act as PAMPs and are recognized by PRRs on innate immune cells since they cannot directly penetrate the cell membrane due to their large molecular size [31]. Indeed, β -glucans were involved in the pathogenesis of sarcoidosis [32], fungal asthma allergy [33], and idiopathic pulmonary fibrosis (IPF) [34].

Similar to other type II transmembrane CTLRs, Dectin-1 has a single extracellular C-type lectin-like domain (CTLD) connected to single-pass TM by an amino acid stalk region and a single

ITAM/hemITAM-containing CYT [35]. In addition, Dectin-1 also contains a triacidic domain (DED) for triggering phagocytosis [36]. A “DED” motif sequence precedes the YxxL sequence in both Dectin-1 and CLEC-2 [37].

Upon ligand binding to the CRD, tyrosine residues are phosphorylated, presumably via Src-family kinases (Lyn and/or Fyn), and Syk or Zap-70 kinases are rapidly recruited and activated via their SH2 domains [38]. In contrast to traditional ITAMs, only one tyrosine within a single YxxL motif is sufficient to mediate an interaction with Syk [39]. How does Dectin-1 bind Syk with a single “hemITAM”? Specific residues may stabilize the interaction between Dectin-1 and Syk within the CYT, or Dectin-1 may dimerize or form higher-order complexes once bound by a ligand [40]. In addition, Syk is more readily activated by autophosphorylation than is Zap-70 [41].

Syk is a 72-KDa nonreceptor tyrosine kinase that consists of two N-terminal Src homology 2 (SH2) motif (SH2-N) and C-terminal SH2 motif (SH2-C) domains separated by two interdomains: A and B [42]. Syk is activated upon binding of the tandem SH2 domains to the ITAM, and an increase in Syk catalytic activity results in autophosphorylation of the tyrosine residues in interdomain B to create docking sites for interactions with other signaling molecules [43]. Active Syk is directly associated with members of the VAV and phospholipase C γ (PLC γ) families, the p85 α subunit of phosphoinositide 3-kinase (PI3K), and SH2 domain-containing leukocyte protein 76 (SLP76) and SLP65 [44].

Dectin-1 can switch on two signaling cascades, the Syk-dependent and Syk-independent pathways, via Raf-1 to induce immune responses [45]. The activation of NF- κ B is a significant outcome [46]. The canonical pathway initiated via activation of Syk and subsequent phosphorylation of PLC γ 2 enables the activation of the caspase-recruitment domain family 9 (CARD9)-B cell lymphoma 10 (BCL10)-mucosa-associated lymphoid tissue lymphoma translocation gene 1 MALT1/CARD9-BCL10-MALT1 (CBM) complex via PKC δ . The CBM complex then activates I κ B kinase (IKK), releasing NF- κ B subunits p65 and c-Rel:p50, which are translocated into the nucleus, where they regulate gene transcription [18]. Nevertheless, CARD9 is useless for antigen receptor signaling based on Carma1 as a link to Bcl10–Malt1 [47]. Additionally, Dectin-1 stimulates a noncanonical pathway utilizing NF- κ B-inducing kinase (NIK)-dependent, but CARD9-independent, activation of the NF- κ B subunit RelB:p52 [48].

Dectin-1 signaling activates dendritic cells (DCs), converting Treg into Th17 and IL-17 responses [49]. The Dectin-1/Syk pathway, but independently of TLRs, can also bridge innate immunity to the adaptive immune system via CD4+ T-helper cells, B cells, and CD8+ cytotoxic T cells [50]. Only TLR-4 cooperates with Dectin-1 to induce adaptive Th17 immunity against fungal infection [51].

The Syk-independent pathway of Dectin-1 is mediated through the DED involved with Raf-1 activation, leading to the phosphorylation and permitting the subsequent acetylation of the NF- κ B p65 subunit or convergence with noncanonical pathways at the level of NF- κ B [18]. Raf-1 activation enhances the expression of some Syk-dependent cytokines, including IL-10, IL-12 p35, IL-12/23 p40, IL-6, and IL-1 β , but negatively regulates the RELB-dependent cytokine IL-23 p19 [22]. In addition, Dectin-1 signaling through the Raf-1 pathway induces immunological memory via functional reprogramming to protect against reinfection [52].

In addition to its role in the NF- κ B pathway, Dectin-1 signaling results in the activation of p38, extracellular signal-regulated kinase (ERK), and JUN-N/amino-terminal kinase (JNK) cascades. CARD9 activates Dectin-1-induced ERK activation by linking Ras-GRF1 to H-Ras [53] and stimulates the receptors Nod2-associated p38 and JNK23 [54]. Additionally, Dectin-1-triggered nuclear factor of activated T cells (NFAT)/calcineurin depends on Syk activation of PLC γ followed by soluble IP3 binding with endoplasmic Ca²⁺ channels, leading to the dephosphorylation and translocation of NFAT into the nucleus of T cells [18]. NFAT activation in macrophages and DCs regulates the induction of early growth response (EGR) 2 and EGR 3 transcription factors and the key inflammatory mediators cyclooxygenase-2 (COX-2), interleukin-2 (IL-2), IL-10, and IL-12p70 [55]. The mechanisms of the signaling cascade of Dectin-1 are described in Figure 2.




Figure 2. Signaling cascade of Dectin-1. The binding of β -glucan on the CRD induces phosphorylation of YxxL (hemITAM), which in turn initiates the recruitment of Syk to the two phosphorylated receptors and other cascades. (1) The canonical Syk-dependent pathway. Active Syk phosphorylates PLC γ 2, enabling the subsequent activation of the CBM complex via PKC δ . The CBM complex removes its inhibitor, I κ B, through activation of the IKK complex and stimulates all NF- κ B subunits. (2) The noncanonical Syk-dependent pathway. Dectin-1 utilizes NIK-dependent but CARD9-independent activation of the NF- κ B subunit RelB: p52, leading to the activation of NF- κ B RelB and p52. The Raf-1-mediated/Syk-independent pathway can abrogate this pathway. (3) The Syk-independent pathway mediated through DED involves Raf-1 and the activation of NF- κ B p50. (4) Activation of NLRP3, NFAT/calcineurin, and ERK/JUN via Dectin-1-ky depends on PLC γ 2; Caspase 1 induces pro-IL-1 β to IL-1 β . The activation of NF- κ B, NLRP3, NFAT, ERK/JUN, and MAPK results in the modification of gene transcription, including that of cytokines and chemokines.

2.2. ITIM-Bearing CTLRs

The first ITIM was recognized in a family of low-affinity Fc receptors for immunoglobulin G (IgG) (Fc γ RIIB) that coaggregated with BCR, inhibiting mouse B-cell activation; however, Fc γ RIIB was also shown to inhibit TCR-dependent T-cell and FcR-dependent mast cell activation [56]. These observations make clear that the termination of immune responses is not merely due to the loss of activating signals; hence, the paradigm focuses on how the coligation of ITAM- and ITIM-containing coreceptors results in the attenuation or inhibition of cellular response [57]. The ITIM present in the CYT with the prototype 6-amino acid ITIM sequence is (Ile/Val/Leu/Ser)-X-Tyr-X-X-(Leu/Val), where X denotes any amino acid [58]. Recent evidence indicates that, under specific conditions, incomplete phosphorylation of ITAM/ITIM may paradoxically lead to the transduction of negative (ITAMi) and positive (ITIMa) signaling [59].

Upon the coaggregation with activating receptors, tyrosine phosphorylation of ITIMs provides docking sites for SH2 domain-containing inositol phosphatase (SHIP-1 and SHIP-2) or SH2 domain-containing protein tyrosine phosphatase (SHP-1 and SHP-2) [60]. SHIP contains a phosphatase domain, an N-terminal SH2 domain, a pleckstrin homology-related (PH-R) domain, and a C-terminus [61].

In addition, SHP is a nonreceptor protein tyrosine phosphatase (PTP) that has an N-terminal SH2, followed by a catalytic domain/PTP domain and a C-SH2 terminus tail [62].

SHIP recruitment to the ITIM of Fc γ RIIB is a dominant mechanism controlling SHIP activity and B cell activation via the PI3K pathway [63]. The PI3K pathway is a target substrate for SHIP through the hydrolyzation of the membrane phosphoinositide PI(3,4,5)P3 to PI(3,4)P2, whereas SHP-1 directly removes the phosphate groups on tyrosine [64].

Both SHPs modulate cellular signaling that involves PI3K, Akt, Janus kinase 2 (JAK2), signal transducer and activator of transcription proteins (STAT), and MAPK [65]. Interestingly, SHPs are involved in several cellular activities, including the regulation of cell growth [66] and MAPK activity [67].

One of the myeloid inhibitory CTLRs is MICL, which can inhibit cellular activation mediated by other immunoreceptors. However, intermolecular interactions between immunoregulatory receptor families or receptor crosstalk among ITIM-bearing CTLRs may not always reflect the simple recruitment of phosphatases and the inhibition of Syk signaling [22].

MICL (DCAL-2). Human MICL is expressed in most myeloid cells, such as granulocytes, monocytes, macrophages, and DCs, but not lymphocytes [68]. It has three isoforms: α , β , and γ , with the β -isoform lacking a transmembrane domain and γ -isoforms lacking the CTLD [18]. Human MICL is highly N-glycosylated in primary cells with various levels of glycosylation of other cell types, but the receptors appear to be expressed as monomers [69]. The specific ligands for MICL are not well defined; however, MCL might bind trehalose dimycolate (TDM) [70].

MICL contains a single ITIM in its CYT that can associate with SHP-1 and SHP-2, but not SHIPs, to modulate cellular activity [71]. MICL induces ERK activation, and its coengagement with TLR4 suppresses IL-12 expression and the polarization of naive T cells into Th1 cells [72]. However, the effect of SHP1 and SHP2 on ERK activation does not always lead to increase activity; therefore, it remains to be determined whether this is a downstream pathway of MICL [73]. The signaling networks of MICL are described in Figure 3.




Figure 3. The signaling networks of MICL. The ITIM motif within MICL interacts with SHP-1 and SHP-2. MICL inhibits cytokine transcription instigated by other receptors. ERK may suppress IL-12 expression and the polarization of Th1 cells, whereas another signaling induces their activation through MAPK. Dashed arrows represent a pathway that has yet to be fully defined.

3. Immune Mechanisms in Fibrosing Interstitial Lung Diseases

ILD encompasses a large and heterogeneous group of parenchymal lung disorders, which may be related to systemic diseases or environmental exposure and unknown causes [74]. One of the most common types of ILD is IPF, a progressive fibrosing ILD that is characterized by a decline in lung function and predominantly affects older adults with a histologic pattern of usual interstitial pneumonia (UIP) [75].

Patients with certain other types of chronic fibrosing ILD are also at risk of developing a progressive phenotype, such as idiopathic nonspecific interstitial pneumonia (NSIP), unclassifiable idiopathic interstitial pneumonia, autoimmune ILDs, sarcoidosis, chronic hypersensitivity pneumonitis (HP), asbestosis or silicosis [76].

The pathogenesis of IPF is unclear; however, chronic and/or repetitive microinjuries of the alveolar epithelium are considered triggers of the disease [77]. Injury from toxic particles or infectious agents triggers inflammatory responses leading to an imbalance of cytokines, increases in free radicals, release of growth factors, and the development of lung fibrosis [78].

Dysregulated activation of Wnt/ β -catenin signaling, inflammasomes, CC chemokine ligand 18 (CCL18), M1/M2 macrophage polarization, IL-17, IL-6, IL-1 β , and transforming growth factor-beta (TGF- β) are immune cells and mediators involved in IPF [79]. Additionally, a dominant mechanism through which innate immune cells adopt fibrosis-promoting properties through PRRs is implicated in a rapidly progressive form of IPF [80].

ILD tends to impair immunity; thus, patients have a higher risk of fungal colonization, which plays a prominent role in the deterioration in the condition of people with the disease [81]. A recent study from China showed that patients with connective tissue diseases (CTDs) that have underlying interstitial pneumonia and who were previously treated with prednisone, or multiple antibiotics, were more likely to develop invasive pulmonary fungal infections (IPFIs) [82]. However, Dectin-1 is a key player in IL-17 production in the pulmonary defense against *Aspergillus fumigatus* [83,84].

Compared to other PRRs, particularly TLRs, the involvement of CTLRs in ILD is enigmatic. Nevertheless, the role of immunoregulatory CTLRs in regulating inflammation and homeostasis demonstrates that these receptors perhaps modulate inflammation-associated lung diseases.

4. Immunoregulatory Receptors as A Novel Therapeutic Targets for ILD

Corticosteroids are the recommended drug for either mono- or combination therapy with other immune modulators, especially for patients with acute exacerbation of the disease [85]. Currently, clinical trials with novel drugs, mainly antifibrosis, anti-cytokine, and immunoregulatory drugs, are being investigated in various trial phases [86]. Dectin-1, acting directly and indirectly, is involved with the pathogenesis of ILD due to its role in regulating gene transcription, including genes of the cytokines and chemokines that are involved in inflammation and fibrosis.

The proinflammatory cytokine interleukin-17 (IL-17) is necessarily implicated in several chronic inflammatory diseases that often culminate in organ damage followed by impaired wound healing and fibrosis development [87]. DCs are converted into hybrid Th cells producing IL-17 upon Dectin-1 stimulation [49]. Furthermore, IL-17 has roles in the acute exacerbation of idiopathic pulmonary fibrosis via a Dectin-1-dependent mechanism [88] and the development of fibrosis in experimental HP [89,90].

Dectin-1 is also involved in regulating the susceptibility of a patient with cystic fibrosis (CF) [91–93] and asthma [94]. Expression of CXCR4⁺-associated Dectin-1 is prominent in fungal cystic fibrosis lung disease; therefore, it may serve as a potential biomarker and therapeutic target in fungal cystic fibrosis lung disease.

The high level of CCL18 in patients with fibrotic lung diseases is indicative of pulmonary fibrotic activity [95] and is a potential biomarker for IPF [96] and for the early identification of progressive ILD [97]. Moreover, high concentrations of Dectin-1-associated IL-10 and CCL18 induce the polarization shift of macrophages toward an alternatively activated macrophage (M2) phenotype in lung fibrosis [98,99]. A recent study revealed that Dectin-1 may inhibit the secretion of CCL18 and may

be valuable as a therapeutic agent to prevent M2 macrophage polarization and progressive fibrotic lung disease [100].

In line with the role of Dectin-1 in innate immunity and homeostasis, the Syk signaling pathway is involved in the mechanism of parenchymal lung fibrosis. Multiple pathways of protein-tyrosine kinases, such as Syk, Src, and Fyn, are involved in promoting fibroblast proliferation and matrix production [101] and play critical roles in the pathogenesis of pulmonary fibrosis [102]. The Syk inhibitor fostamatinib prevents bleomycin-induced fibrosis and inflammation in the skin and lung by reducing Syk phosphorylation and TGF- β expression [103].

Intriguingly, Dectin-1, via interactions with Syk and the Nod-like receptor protein 3 (NLRP3) inflammasome, is associated with the activation of NF- κ B, which then induces proinflammatory cytokines such as IL-6, TNF- α , and pro-IL-1 β [104]. Syk associates directly with apoptosis-associated speck-like protein (ASC) and NLRP3 but interacts indirectly with procaspase-1; specifically, Syk phosphorylates ASC at Y146 and Y187 residues to enhance ASC oligomerization and the recruitment of procaspase-1 [105]. NLRP3 is essential in the progression of pulmonary fibrosis [106]. Activation of the NLRP3 inflammasome induces caspase-1 cleavage and then leads to the secretion of the profibrotic mediators IL-1 β and IL-18 [107].

In contrast to Dectin-1, MICL is involved indirectly through protein intracellular cascades in fibrosis. As previously noted, SHP is involved in the PI3K/Akt pathway. The activation of PI3K/Akt signaling can modulate β -catenin-mediated Wnt signaling via the inhibition of β -catenin nuclear localization and regulation of glycogen synthase kinase 3 β (GSK3 β) phosphorylation [108,109]. Recently, SHP-1 was found to regulate pulmonary fibrosis via the inhibition of β -catenin in lung epithelial cells [110]. Additionally, mice deficient in SHP-1 were found to more susceptible to bleomycin-induced lung injury and fibrosis [111]. However, we assume that PI3K/Akt-dependent Wnt/ β -catenin is not directly related to MICL.

Wnt/ β -catenin plays a critical role in development and adult tissue homeostasis, especially during abnormal wound repair and fibrogenesis [112]. Additionally, the interaction of TGF- β and the canonical Wnt/ β -catenin pathway stimulates fibroblast accumulation and myofibroblasts [113,114] and the development of pulmonary fibrosis [115]. Therefore, blocking Wnt/ β -catenin signaling attenuates myofibroblast differentiation of lung resident mesenchymal stem cells and pulmonary fibrosis [116] and bleomycin-induced pulmonary fibrosis [117].

MAPK-phosphatase (MKP)-5 is required for the induction of changes to lung fibroblasts and bleomycin-induced lung fibrosis [118]. Activation of the MAPK/ERK signaling cascade in the lungs in human fibrosis is associated with fibrogenesis, including fibroblast growth, proliferation, and survival [119].

5. Conclusions

Both Dectin-1 and Syk have essential roles in NLRP3/NFAT-associated fibrosis via caspase-1, which induces the transformation of IL-1 β from pro-IL-1 β . Also, Dectin-1 upregulates the production of IL-17 and TGF- β . The discovery that the β -glucan ligand binds to Dectin-1 in M2 macrophages has been a breakthrough in the use of Dectin-1 as a potential biomarker and targeted treatment in fibrosing ILD.

In contrast to Dectin-1, MICL indirectly affects the mechanism of fibrosis via intracellular signaling proteins, such as SHP, Wnt/ β -catenin, and PI3K/Akt. Even though the mechanism remains unclear, the role of immunoregulatory receptors of CLR in fibrosing ILD is relevant and exciting, particularly for its clinical implications. Additional studies are required to shed light on the role of Dectin-1 and especially MICL in the pathogenesis of fibrosing ILD.

Author Contributions: Conceptualization, W.I.E., T.N., H.H., and R.Y.; resources, W.I.E., and T.N.; writing—preparation of the original draft, W.I.E., and T.N.; writing—review and editing, W.I.E., T.N., H.H., and R.Y.; supervision, R.Y.; project administration, R.Y. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Acknowledgments: We would like to express our gratitude to members of the Division of Respiratory Medicine of Kobe University Graduate School of Medicine and Department of Pulmonology and Respiratory Medicine, Medical Faculty of Airlangga University, for their helpful discussions and contributions.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

ASC	Apoptosis-associated speck-like protein
BCL10	B cell lymphoma 10
CARD9	Caspase-recruitment domain family 9
CBM	CARD9-Bcl10-Malt1
CBP	CSK-binding Protein
CF	Cystic fibrosis
CLRs	C-type lectin receptors
CCL18	CC chemokine ligand 18
CRD	Carbohydrate-recognition domains
CSK	Carboxy (C)-terminal Src kinase
CTDs	Connective tissue diseases
CTLD	C-type lectin-like domain
CTLRs	C-type lectin-like receptors
CYT	Cytoplasmic Tail
DAMPs	Damage-associated molecular patterns
DC	Dendritic cell
Dectin-1	Dendritic cell-associated C-type lectin-1
EGR 2	Early growth response 2
EGR 3	Early growth response 3
ERK	Extracellular signal-regulated kinase
FcR γ	Fc receptor γ -chain
GSK3 β	Glycogen synthase kinase 3 β
HP	Hypersensitivity Pneumonitis
IFN	Interferon
IgG	Immunoglobulin G
IKK	I κ B kinase
IPFIs	Invasive pulmonary fungal infections
PLC γ	Phospholipase C γ
IL-10	Interleukin-10
IL-12	Interleukin-12
IL-17	Interleukin-17
IL-18	Interleukin-18
IL-1 β	Interleukin-1 β
IL-2	Interleukin-2
ILD	Interstitial lung diseases
IPF	Idiopathic pulmonary fibrosis
ITAMi	Immunoreceptor tyrosine-based activation motif inhibitor
ITAMs	Immunoreceptor tyrosine-based activation motifs
ITIMa	Immunoreceptor tyrosine-based inhibition motifs activation
ITIMs	Immunoreceptor tyrosine-based inhibition motifs
LAB	Linker for activation of B cells
JAK2	Janus kinase 2
JNK	JUN- N/amino terminal kinase
LAT	Linker for activation of T cells
LIME	LCK-interacting membrane protein

MALT1	Mucosa-associated lymphoid tissue lymphoma translocation gene 1
MAPK	Mitogen-activating protein kinase
MKP	MAPK-phosphatase
M-CSF	Macrophage-colony stimulating factor
NFAT	Nuclear factor of activated T cells
NF- $\kappa\beta$	Nuclear factor- $\kappa\beta$
NIK	NF- $\kappa\beta$ -inducing kinase
NLRP3	Nod-like receptor protein 3
NLRs	NOD-like receptors
NOD	Nucleotide-binding oligomerization domain
NTAL	Non-T-cell activation linker
PAG	Protein associated with GEMs
PAMPs	Pathogen-associated molecular patterns
PH-R	Pleckstrin homology-related domains
PTPs	Protein tyrosine phosphatases
RIG-1	Retinoic acid-inducible gene -1
RLRs	RIG-1-like receptors
ROS	Reactive oxygen species
SH2	Src homology 2
SH2-C	C-terminal SH2
SH2-N	N-terminal SH2
SHIP-1	SH2 domain-containing inositol phosphatase 1
SHIP-2	SH2 domain-containing inositol phosphatase 2
SHP-1	SH2-domain-containing protein tyrosine phosphatase 1
SHP-2	SH2-domain-containing protein tyrosine phosphatase 2
SIT	SHP2-interacting TRAP
SLP65	SH2 domain-containing leukocyte protein 65
SLP76	SH2 domain-containing leukocyte protein 76
TDM	Trehalose dimycolate
TLRs	Toll-like receptors
TM	Transmembrane
TRAPs	Transmembrane adaptor proteins
TRIM	TCR-interacting molecule
PI3K	Phosphoinositide 3-KINASE
UIP	Usual interstitial pneumonia

References

1. Gasteiger, G.; D'Osualdo, A.; Schubert, D.A.; Weber, A.; Bruscia, E.M.; Hartl, D. Cellular Innate Immunity: An Old Game with New Players. *J. Innate Immun.* **2017**, *9*, 111–125. [[CrossRef](#)] [[PubMed](#)]
2. Amarante-Mendes, G.P.; Adjemian, S.; Branco, L.M.; Zanetti, L.C.; Weinlich, R.; Bortoluci, K.R. Pattern recognition receptors and the host cell death molecular machinery. *Front. Immunol.* **2018**, *9*, 2379. [[CrossRef](#)] [[PubMed](#)]
3. Takeuchi, O.; Akira, S. Pattern Recognition Receptors and Inflammation. *Cell* **2010**, *140*, 805–820. [[CrossRef](#)] [[PubMed](#)]
4. Weis, W.I.; Taylor, M.E.; Drickamer, K. The C-type lectin superfamily in the immune system. *Immunol. Rev.* **1998**, *163*, 19–34. [[CrossRef](#)]
5. Dambuzza, I.M.; Brown, G.D. C-type lectins in immunity: Recent developments. *Curr. Opin. Immunol.* **2015**, *32*, 21–27. [[CrossRef](#)]
6. Brown, G.D.; Willment, J.A.; Whitehead, L. C-type lectins in immunity and homeostasis. *Nat. Rev. Immunol.* **2018**, *18*, 374–389. [[CrossRef](#)]
7. Seifert, L.; Deutsch, M.; Alothman, S.; Alqunaibit, D.; Werba, G.; Pansari, M.; Pergamo, M.; Ochi, A.; Torres-Hernandez, A.; Levie, E.; et al. Dectin-1 Regulates Hepatic Fibrosis and Hepatocarcinogenesis by Suppressing TLR4 Signaling Pathways. *Cell Rep.* **2015**, *13*, 1909–1921. [[CrossRef](#)]

8. Lech, M.; Anders, H.J. Macrophages and fibrosis: How resident and infiltrating mononuclear phagocytes orchestrate all phases of tissue injury and repair. *Biochim. Biophys. Acta-Mol. Basis Dis.* **2013**, *1832*, 989–997. [[CrossRef](#)]
9. Ricci, M. Immunoregulation in clinical diseases: An overview. *Clin. Immunol. Immunopathol.* **1989**, *50*, S3. [[CrossRef](#)]
10. Fehérvári, Z.; Sakaguchi, S. CD4⁺ Tregs and immune control. *J. Clin. Investig.* **2004**, *114*, 1209–1217. [[CrossRef](#)]
11. da Silva, F.P.; Aloulou, M.; Benhamou, M.; Monteiro, R.C. Inhibitory ITAMs: A matter of life and death. *Trends Immunol.* **2008**, *29*, 366–373. [[CrossRef](#)] [[PubMed](#)]
12. Fei, C.; Pemberton, J.G.; Lillico, D.M.E.; Zwozdesky, M.A.; Stafford, J.L. Biochemical and functional insights into the integrated regulation of innate immune cell responses by teleost leukocyte immune-type receptors. *Biology* **2016**, *5*, 13. [[CrossRef](#)] [[PubMed](#)]
13. Cortes, H.D.; Lillico, D.M.E.; Zwozdesky, M.A.; Pemberton, J.G.; O'Brien, A.; Montgomery, B.C.S.; Wiersma, L.; Chang, J.P.; Stafford, J.L. Induction of phagocytosis and intracellular signaling by an inhibitory channel catfish leukocyte immune-type receptor: Evidence for immunoregulatory receptor functional plasticity in teleosts. *J. Innate Immun.* **2014**, *6*, 435–455. [[CrossRef](#)] [[PubMed](#)]
14. Hořejší, V.; Zhang, W.; Schraven, B. Transmembrane adaptor proteins: Organizers of immunoreceptor signalling. *Nat. Rev. Immunol.* **2004**, *4*, 603–616. [[CrossRef](#)] [[PubMed](#)]
15. Zelensky, A.N.; Gready, J.E. The C-type lectin-like domain superfamily. *Febs J.* **2005**, *272*, 6179–6217. [[CrossRef](#)]
16. Huysamen, C.; Brown, G.D. The fungal pattern recognition receptor, Dectin-1, and the associated cluster of C-type lectin-like receptors. *Fems Microbiol. Lett.* **2009**, *290*, 121–128. [[CrossRef](#)]
17. Chiffolleau, E. C-type lectin-like receptors as emerging orchestrators of sterile inflammation represent potential therapeutic targets. *Front. Immunol.* **2018**, *9*, 227.
18. Plato, A.; Willment, J.A.; Brown, G.D. C-Type lectin-like receptors of the dectin-1 cluster: Ligands and signaling pathways. *Int. Rev. Immunol.* **2013**, *32*, 134–156. [[CrossRef](#)]
19. Hamerman, J.A.; Lanier, L.L. Inhibition of immune responses by ITAM-bearing receptors. *Sci. Stke* **2006**, *2006*, re1. [[CrossRef](#)]
20. Kane, B.A.; Bryant, K.J.; McNeil, H.P.; Tedla, N.T. Termination of immune activation: An essential component of healthy host immune responses. *J. Innate Immun.* **2014**, *6*, 727–738. [[CrossRef](#)]
21. Humphrey, M.B.; Lanier, L.L.; Nakamura, M.C. Role of ITAM-containing adapter proteins and their receptors in the immune system and bone. *Immunol. Rev.* **2005**, *208*, 50–65. [[CrossRef](#)] [[PubMed](#)]
22. Sancho, D.; Reis e Sousa, C. Signaling by Myeloid C-Type Lectin Receptors in Immunity and Homeostasis. *Annu. Rev. Immunol.* **2012**, *30*, 491–529. [[CrossRef](#)] [[PubMed](#)]
23. Hamerman, J.A.; Ni, M.; Killebrew, J.R.; Chu, C.L.; Lowell, C.A. The expanding roles of ITAM adapters FcRγ and DAP12 in myeloid cells. *Immunol. Rev.* **2009**, *232*, 42–58. [[CrossRef](#)] [[PubMed](#)]
24. Palma, A.S.; Feizi, T.; Zhang, Y.; Stoll, M.S.; Lawson, A.M.; Díaz-Rodríguez, E.; Campanero-Rhodes, M.A.; Costa, J.; Gordon, S.; Brown, G.D.; et al. Ligands for the β-glucan receptor, dectin-1, assigned using “designer” microarrays of oligosaccharide probes (neoglycolipids) generated from glucan polysaccharides. *J. Biol. Chem.* **2006**, *281*, 5771–5779. [[CrossRef](#)] [[PubMed](#)]
25. Ariizumi, K.; Shen, G.L.; Shikano, S.; Xu, S.; Ritter, R.; Kumamoto, T.; Edelbaum, D.; Morita, A.; Bergstresser, P.R.; Takashima, A. Identification of a novel, dendritic cell-associated molecule, dectin-1, by subtractive cDNA cloning. *J. Biol. Chem.* **2000**, *275*, 20157–20167. [[CrossRef](#)]
26. Taylor, P.R.; Brown, G.D.; Reid, D.M.; Willment, J.A.; Martinez-Pomares, L.; Gordon, S.; Wong, S.Y.C. The β-Glucan Receptor, Dectin-1, Is Predominantly Expressed on the Surface of Cells of the Monocyte/Macrophage and Neutrophil Lineages. *J. Immunol.* **2002**, *169*, 3876–3882. [[CrossRef](#)]
27. Kato, Y.; Adachi, Y.; Ohno, N. Contribution of N-linked oligosaccharides to the expression and functions of β-glucan receptor, Dectin-1. *Biol. Pharm. Bull.* **2006**, *29*, 1580–1586. [[CrossRef](#)]
28. Goodridge, H.S.; Reyes, C.N.; Becker, C.A.; Katsumoto, T.R.; Ma, J.; Wolf, A.J.; Bose, N.; Chan, A.S.H.; Magee, A.S.; Danielson, M.E.; et al. Activation of the innate immune receptor Dectin-1 upon formation of a Phagocytic synapseTM. *Nature* **2011**, *472*, 471–475.
29. Bordon, Y. Phagocytosis: A synapse for snaps. *Nat. Rev. Immunol.* **2011**, *11*, 371.

30. Goodridge, H.S.; Wolf, A.J.; Underhill, D.M. B-Glucan Recognition By the Innate Immune System. *Immunol. Rev.* **2009**, *230*, 38–50. [[CrossRef](#)]
31. Camilli, G.; Tabouret, G.; Quintin, J. The Complexity of Fungal β -Glucan in Health and Disease: Effects on the Mononuclear Phagocyte System. *Front. Immunol.* **2018**, *9*, 1–9. [[CrossRef](#)] [[PubMed](#)]
32. Tercelj, M.; Salobir, B.; Rylander, R. β -glucan in lymph nodes in sarcoidosis patients. *Eur. Respir. J.* **2016**, *48*, PA828.
33. Lilly, L.M.; Gessner, M.A.; Dunaway, C.W.; Metz, A.E.; Schwiebert, L.; Weaver, C.T.; Brown, G.D.; Steele, C. The β -Glucan Receptor Dectin-1 Promotes Lung Immunopathology during Fungal Allergy via IL-22. *J. Immunol.* **2012**, *189*, 3653–3660. [[CrossRef](#)] [[PubMed](#)]
34. Ali, M.; Dasari, H.; Van Keulen, V.; Egan, A.; Peikert, T.; Carmona, E.M. Microbial Activation of B-cells by Pattern Recognition Receptors Contributes to the Proinflammatory and Profibrotic Milieu in Patients with Idiopathic Pulmonary Fibrosis. *J. Immunol.* **2019**, *202*, 190.20 LP-190.20.
35. Willment, J.A.; Gordon, S.; Brown, G.D. Characterization of the Human β -Glucan Receptor and Its Alternatively Spliced Isoforms. *J. Biol. Chem.* **2001**, *276*, 43818–43823. [[CrossRef](#)]
36. Azad, A.K.; Torrelles, J.B.; Schlesinger, L.S. Mutation in the DC-SIGN cytoplasmic triacidic cluster motif markedly attenuates receptor activity for phagocytosis and endocytosis of mannose-containing ligands by human myeloid cells. *J. Leukoc. Biol.* **2008**, *84*, 1594–1603. [[CrossRef](#)]
37. Hughes, C.E.; Sinha, U.; Pandey, A.; Eble, J.A.; O’Callaghan, C.A.; Watson, S.P. Critical role for an acidic amino acid region in platelet signaling by the HemITAM (hemi-immunoreceptor tyrosine-based activation motif) containing receptor CLEC-2 (C-type lectin receptor-2). *J. Biol. Chem.* **2013**, *288*, 5127–5135. [[CrossRef](#)]
38. Bezbradica, J.S.; Rosenstein, R.K.; Demarco, R.A.; Brodsky, I.; Medzhitov, R. A role for the ITAM signaling module in specifying cytokine-receptor functions. *Nat. Immunol.* **2014**, *15*, 333–342. [[CrossRef](#)]
39. Rogers, N.C.; Slack, E.C.; Edwards, A.D.; Nolte, M.A.; Schulz, O.; Schweighoffer, E.; Williams, D.L.; Gordon, S.; Tybulewicz, V.L.; Brown, G.D.; et al. Syk-dependent cytokine induction by dectin-1 reveals a novel pattern recognition pathway for C type lectins. *Immunity* **2005**, *22*, 507–517. [[CrossRef](#)]
40. Schorey, J.S.; Lawrence, C. The pattern recognition receptor Dectin-1: From fungi to mycobacteria. *Curr. Drug Targets* **2008**, *9*, 123–129. [[CrossRef](#)]
41. Tsang, E.; Giannetti, A.M.; Shaw, D.; Dinh, M.; Tse, J.K.Y.; Gandhi, S.; Ho, A.; Wang, S.; Papp, E.; Bradshaw, J.M. Molecular mechanism of the Syk activation switch. *J. Biol. Chem.* **2008**, *283*, 32650–32659. [[CrossRef](#)] [[PubMed](#)]
42. Grädler, U.; Schwarz, D.; Dresing, V.; Musil, D.; Bomke, J.; Frech, M.; Greiner, H.; Jäkel, S.; Rysiok, T.; Müller-Pompalla, D.; et al. Structural and biophysical characterization of the Syk activation switch. *J. Mol. Biol.* **2013**, *425*, 309–333. [[CrossRef](#)] [[PubMed](#)]
43. Sada, K.; Takano, T.; Yanagi, S.; Yamamura, H. Structure and function of Syk protein-tyrosine kinase. *J. Biochem.* **2001**, *130*, 177–186. [[CrossRef](#)] [[PubMed](#)]
44. Mócsai, A.; Ruland, J.; Tybulewicz, V.L.J. The SYK tyrosine kinase: A crucial player in diverse biological functions. *Nat. Rev. Immunol.* **2010**, *10*, 387–402. [[CrossRef](#)]
45. Gringhuis, S.I.; den Dunnen, J.; Litjens, M.; van der Vlist, M.; Wevers, B.; Bruijns, S.C.M.; Geijtenbeek, T.B.H. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF- κ B activation through Raf-1 and Syk. *Nat. Immunol.* **2009**, *10*, 203–213. [[CrossRef](#)] [[PubMed](#)]
46. Kingeter, L.M.; Lin, X. C-type lectin receptor-induced NF- κ B activation in innate immune and inflammatory responses. *Cell. Mol. Immunol.* **2012**, *9*, 105–112. [[CrossRef](#)]
47. Gross, O.; Gewies, A.; Finger, K.; Schäfer, M.; Sparwasser, T.; Peschel, C.; Förster, I.; Ruland, J. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. *Nature* **2006**, *442*, 651–656. [[CrossRef](#)]
48. Shih, V.F.S.; Tsui, R.; Caldwell, A.; Hoffmann, A. A single NF κ B system for both canonical and non-canonical signaling. *Cell Res.* **2011**, *21*, 86–102. [[CrossRef](#)]
49. Osorio, F.; LeibundGut-Landmann, S.; Lochner, M.; Lahl, K.; Sparwasser, T.; Eberl, G.; Reis e Sousa, C. DC activated via dectin-1 convert Treg into IL-17 producers. *Eur. J. Immunol.* **2008**, *38*, 3274–3281. [[CrossRef](#)]
50. LeibundGut-Landmann, S.; Osorio, F.; Brown, G.D.; Sousa, C.R.E. Stimulation of dendritic cells via the dectin-1/Syk pathway allows priming of cytotoxic T-cell responses. *Blood* **2008**, *112*, 4971–4980. [[CrossRef](#)]
51. Loures, F.V.; Araújo, E.F.; Feriotti, C.; Bazan, S.B.; Calich, V.L.G. TLR-4 cooperates with Dectin-1 and mannose receptor to expand Th17 and Tc17 cells induced by *Paracoccidioides brasiliensis* stimulated dendritic cells. *Front. Microbiol.* **2015**, *6*, 1–11. [[CrossRef](#)] [[PubMed](#)]

52. Quintin, J.; Saeed, S.; Martens, J.H.A.; Giamarellos-Bourboulis, E.J.; Ifrim, D.C.; Logie, C.; Jacobs, L.; Jansen, T.; Kullberg, B.J.; Wijmenga, C.; et al. *Candida albicans* infection affords protection against reinfection via functional reprogramming of monocytes. *Cell Host Microbe* **2012**, *12*, 223–232. [[CrossRef](#)]
53. Jia, X.M.; Tang, B.; Zhu, L.L.; Liu, Y.H.; Zhao, X.Q.; Gorjestani, S.; Hsu, Y.M.S.; Yang, L.; Guan, J.H.; Xu, G.T.; et al. CARD9 mediates Dectin-1-induced ERK activation by linking Ras-GRF1 to H-Ras for antifungal immunity. *J. Exp. Med.* **2014**, *211*, 2307–2321. [[CrossRef](#)] [[PubMed](#)]
54. LeibundGut-Landmann, S.; Groß, O.; Robinson, M.J.; Osorio, F.; Slack, E.C.; Tsoni, S.V.; Schweighoffer, E.; Tybulewicz, V.; Brown, G.D.; Ruland, J.; et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. *Nat. Immunol.* **2007**, *8*, 630–638. [[CrossRef](#)] [[PubMed](#)]
55. Goodridge, H.S.; Simmons, R.M.; Underhill, D.M. Dectin-1 Stimulation by *Candida albicans* Yeast or Zymosan Triggers NFAT Activation in Macrophages and Dendritic Cells. *J. Immunol.* **2007**, *178*, 3107–3115. [[CrossRef](#)] [[PubMed](#)]
56. Daëron, M.; Jaeger, S.; Du Pasquier, L.; Vivier, E. Immunoreceptor tyrosine-based inhibition motifs: A quest in the past and future. *Immunol. Rev.* **2008**, *224*, 11–43. [[CrossRef](#)] [[PubMed](#)]
57. Billadeau, D.D.; Leibson, P.J. ITAMs versus ITIMs: Striking a balance during cell regulation. *J. Clin. Invest.* **2002**, *109*, 161–168. [[CrossRef](#)] [[PubMed](#)]
58. Ravetch, J.V.; Lanier, L.L. Immune inhibitory receptors. *Science* **2000**, *290*, 84–89. [[CrossRef](#)]
59. Waterman, P.M.; Cambier, J.C. The conundrum of inhibitory signaling by ITAM-containing immunoreceptors: Potential molecular mechanisms. *Febs Lett.* **2010**, *584*, 4878–4882. [[CrossRef](#)]
60. Coxon, C.H.; Geer, M.J.; Senis, Y.A. ITIM receptors: More than just inhibitors of platelet activation. *Blood* **2017**, *129*, 3407–3418. [[CrossRef](#)]
61. Pauls, S.D.; Marshall, A.J. Regulation of immune cell signaling by SHIP1: A phosphatase, scaffold protein, and potential therapeutic target. *Eur. J. Immunol.* **2017**, *47*, 932–945. [[CrossRef](#)] [[PubMed](#)]
62. Wang, W.; Liu, L.; Song, X.; Mo, Y.; Komma, C.; Bellamy, H.D.; Zhao, Z.J.; Zhou, G.W. Crystal structure of human protein tyrosine phosphatase SHP-1 in the open conformation. *J. Cell. Biochem.* **2011**, *112*, 2062–2071. [[CrossRef](#)] [[PubMed](#)]
63. Pauls, S.D.; Ray, A.; Hou, S.; Vaughan, A.T.; Cragg, M.S.; Marshall, A.J. FcγRIIB-Independent Mechanisms Controlling Membrane Localization of the Inhibitory Phosphatase SHIP in Human B Cells. *J. Immunol.* **2016**, *197*, 1587–1596. [[CrossRef](#)] [[PubMed](#)]
64. Bounab, Y.; Getahun, A.; Cambier, J.C.; Daëron, M. Phosphatase regulation of immunoreceptor signaling in T cells, B cells and mast cells. *Curr. Opin. Immunol.* **2013**, *25*, 313–320. [[CrossRef](#)]
65. Chong, Z.Z.; Maiese, K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: Diversified control of cell growth, inflammation, and injury. *Histol. Histopathol.* **2007**, *22*, 1251–1267.
66. Yi, T.; Mui, A.L.; Krystal, G.; Ihle, J.N. Hematopoietic cell phosphatase associates with the interleukin-3 (IL-3) receptor beta chain and down-regulates IL-3-induced tyrosine phosphorylation and mitogenesis. *Mol. Cell. Biol.* **1993**, *13*, 7577–7586. [[CrossRef](#)]
67. Pani, G.; Kozlowski, M.; Cambier, J.C.; Mills, G.B.; Siminovitch, K.A. Identification of the tyrosine phosphatase PTPIC as a B cell antigen receptor-associated protein involved in the regulation of B cell signaling. *J. Exp. Med.* **1995**, *181*, 2077–2084. [[CrossRef](#)]
68. Marshall, A.S.J.; Willmen, J.A.; Lin, H.H.; Williams, D.L.; Gordon, S.; Brown, G.D. Identification and Characterization of a Novel Human Myeloid Inhibitory C-type Lectin-like Receptor (MICL) That Is Predominantly Expressed on Granulocytes and Monocytes. *J. Biol. Chem.* **2004**, *279*, 14792–14802. [[CrossRef](#)]
69. Marshall, A.S.J.; Willment, J.A.; Pyz, E.; Dennehy, K.M.; Reid, D.M.; Dri, P.; Gordon, S.; Wong, S.Y.C.; Brown, G.D. Human MICL (CLEC12A) is differentially glycosylated and is down-regulated following cellular activation. *Eur. J. Immunol.* **2006**, *36*, 2159–2169. [[CrossRef](#)]
70. Foster, A.J.; Bird, J.H.; Timmer, M.S.M.; Stocker, B.L. The ligands of C-type lectins. In *C-Type Lectin Receptors in Immunity*; Springer: Tokyo, Japan, 2016; pp. 191–215. ISBN 9784431560159.
71. Pyz, E.; Huysamen, C.; Marshall, A.S.J.; Gordon, S.; Taylor, P.R.; Brown, G.D. Characterisation of murine MICL (CLEC12A) and evidence for an endogenous ligand. *Eur. J. Immunol.* **2008**, *38*, 1157–1163. [[CrossRef](#)]
72. Chen, C.H.; Floyd, H.; Olson, N.E.; Magaletti, D.; Li, C.; Draves, K.; Clark, E.A. Dendritic-cell-associated C-type lectin 2 (DCAL-2) alters dendritic-cell maturation and cytokine production. *Blood* **2006**, *107*, 1459–1467. [[CrossRef](#)] [[PubMed](#)]

73. Geijtenbeek, T.B.H.; Gringhuis, S.I. Signalling through C-type lectin receptors: Shaping immune responses. *Nat. Rev. Immunol.* **2009**, *9*, 465–479. [[CrossRef](#)] [[PubMed](#)]
74. Maher, T.M.; Wuyts, W. Management of Fibrosing Interstitial Lung Diseases. *Adv. Ther* **2019**, *36*, 1518–1531. [[CrossRef](#)] [[PubMed](#)]
75. Olson, A.L.; Swigris, J.J. Idiopathic Pulmonary Fibrosis: Diagnosis and Epidemiology. *Clin. Chest Med.* **2012**, *33*, 41–50. [[CrossRef](#)] [[PubMed](#)]
76. Cottin, V.; Wollin, L.; Fischer, A.; Quaresma, M.; Stowasser, S.; Harari, S. Fibrosing interstitial lung diseases: Knowns and unknowns. *Eur. Respir. Rev.* **2019**, *28*, 180100. [[CrossRef](#)]
77. Plantier, L.; Cazes, A.; Dinh-Xuan, A.T.; Bancal, C.; Marchand-Adam, S.; Crestani, B. Physiology of the lung in idiopathic pulmonary fibrosis. *Eur. Respir. Rev.* **2018**, *27*, 170062. [[CrossRef](#)]
78. Hügler, T. Immunology of fibrotic lung disease: Managing infections whilst preventing autoimmunity? *J. Inflamm. Res.* **2011**, *4*, 21–27.
79. Kolahian, S.; Fernandez, I.E.; Eickelberg, O.; Hartl, D. Immune mechanisms in pulmonary fibrosis. *Am. J. Respir. Cell Mol. Biol.* **2016**, *55*, 309–322. [[CrossRef](#)]
80. Desai, O.; Winkler, J.; Minasyan, M.; Herzog, E.L. The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis. *Front. Med.* **2018**, *5*, 43. [[CrossRef](#)]
81. Sivokozov, I.; Lovacheva, O.; Shmelev, E.; Larionova, E. Fungal colonization in interstitial lung diseases. *Eur. Respir. J.* **2011**, *38*, 3749.
82. Ge, H.F.; Liu, X.Q.; Zhu, Y.Q.; Chen, H.Q.; Chen, G.Z. Invasive pulmonary fungal infections in patients with connective tissue disease: A retrospective study from northern China. *Braz. J. Med. Biol. Res.* **2016**, *49*. [[CrossRef](#)] [[PubMed](#)]
83. Werner, J.L.; Metz, A.E.; Horn, D.; Schoeb, T.R.; Hewitt, M.M.; Schwiebert, L.M.; Faro-Trindade, I.; Brown, G.D.; Steele, C. Requisite Role for the Dectin-1 β -Glucan Receptor in Pulmonary Defense against *Aspergillus fumigatus*. *J. Immunol.* **2009**, *182*, 4938–4946. [[CrossRef](#)] [[PubMed](#)]
84. Werner, J.L.; Steele, C. Innate Receptors and Cellular Defense against Pulmonary Infections. *J. Immunol.* **2014**, *193*, 3842–3850. [[CrossRef](#)] [[PubMed](#)]
85. Raghu, G.; Collard, H.R.; Egan, J.J.; Martinez, F.J.; Behr, J.; Brown, K.K.; Colby, T.V.; Cordier, J.F.; Flaherty, K.R.; Lasky, J.A.; et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. *Am. J. Respir. Crit. Care Med.* **2011**, *183*, 788–824. [[CrossRef](#)]
86. Bouros, D.; Antoniou, K.M. Current and future therapeutic approaches in idiopathic pulmonary fibrosis. *Eur. Respir. J.* **2005**, *26*, 693–702. [[CrossRef](#)]
87. Ramani, K.; Biswas, P.S. Interleukin-17: Friend or foe in organ fibrosis. *Cytokine* **2019**, *120*, 282–288. [[CrossRef](#)]
88. Weng, D.; Chen, X.Q.; Li, H.P.; Ge, B.X. IL-17 And MIG Contribute To Fungi-Induced Acute Exacerbation Of Idiopathic Pulmonary Fibrosis Via A Dectin-1 Dependent Mechanism. In *Proceedings of the A61. LUNG FIBROSIS: ANIMAL MODELS II*; American Thoracic Society: New York, NY, USA, 2014; p. A1983.
89. Hasan, S.A.; Eksteen, B.; Reid, D.; Paine, H.V.; Alansary, A.; Johannson, K.; Gwozd, C.; Goring, K.A.R.; Vo, T.; Proud, D.; et al. Role of IL-17A and neutrophils in fibrosis in experimental hypersensitivity pneumonitis. *J. Allergy Clin. Immunol.* **2013**, *131*, 1663–1673.e5. [[CrossRef](#)]
90. Higashino-Kameda, M.; Yabe-Wada, T.; Matsuba, S.; Takeda, K.; Anzawa, K.; Mochizuki, T.; Makimura, K.; Saijo, S.; Iwakura, Y.; Toga, H.; et al. A critical role of Dectin-1 in hypersensitivity pneumonitis. *Inflamm. Res.* **2016**, *65*, 235–244. [[CrossRef](#)]
91. Ralhan, A.; Frey, N.; Schroth, C.; Singh, A.; Hector, A.; Hartl, D. Regulation of dectin-1 in cystic fibrosis bronchial epithelial cells during host pathogen interactions. *Eur. Respir. J.* **2016**, *48*, PA4858.
92. Griffiths, J.S.; Thompson, A.; Stott, M.; Benny, A.; Lewis, N.A.; Taylor, P.R.; Forton, J.; Herrick, S.; Orr, S.J.; McGreal, E.P. Differential susceptibility of Dectin-1 isoforms to functional inactivation by neutrophil and fungal proteases. *Faseb J.* **2018**, *32*, 3385–3397. [[CrossRef](#)]
93. De Rose, V.; Molloy, K.; Gohy, S.; Pilette, C.; Greene, C.M. Airway epithelium dysfunction in cystic fibrosis and COPD. *Mediat. Inflamm.* **2018**, *2018*, 1309746. [[CrossRef](#)] [[PubMed](#)]
94. Ramaprakash, H.; Ito, T.; Standiford, T.J.; Kunkel, S.L.; Hogaboam, C.M. Toll-like receptor 9 modulates immune responses to *Aspergillus fumigatus* conidia in immunodeficient and allergic mice. *Infect. Immun.* **2009**, *77*, 108–119. [[CrossRef](#)] [[PubMed](#)]

95. Prasse, A.; Pechkovsky, D.V.; Toews, G.B.; Schäfer, M.; Eggeling, S.; Ludwig, C.; Germann, M.; Kollert, F.; Zissel, G.; Müller-Quernheim, J. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. *Arthritis Rheum.* **2007**, *56*, 1685–1693. [[CrossRef](#)] [[PubMed](#)]
96. Niu, R.; Li, X.; Zhang, Y.; Wang, H.; Wang, Y.; Zhang, Y.; Wang, W. (No Title). *Int. J. Clin. Exp. Pathol.* **2016**, *9*, 8922–8932.
97. Hoffmann-Vold, A.M.; Tennøe, A.H.; Garen, T.; Midtvedt, Ø.; Abraitte, A.; Aaløkken, T.M.; Lund, M.B.; Brunborg, C.; Aukrust, P.; Ueland, T.; et al. High Level of Chemokine CCL18 Is Associated With Pulmonary Function Deterioration, Lung Fibrosis Progression, and Reduced Survival in Systemic Sclerosis. *Chest* **2016**, *150*, 299–306. [[CrossRef](#)]
98. Wermuth, P.J.; Jimenez, S.A. The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases. *Clin. Transl. Med.* **2015**, *4*, 1–19. [[CrossRef](#)]
99. de Gaetano, M.; Crean, D.; Barry, M.; Belton, O. M1- and M2-Type Macrophage Responses Are Predictive of Adverse Outcomes in Human Atherosclerosis. *Front. Immunol.* **2016**, *7*, 275. [[CrossRef](#)]
100. El Taweel, M.; Walker, H.; Mekhael, O.; Vierhout, M.; Padwal, M.; Naiel, S.; Patel, H.; Parthasarathy, P.; Imani, J.; Ayoub, E.; et al. Dectin-1 Is a Marker of Alternatively Activated Macrophages and a Therapeutic Target in Interstitial Fibrotic Lung Diseases. In *Proceedings of the American Thoracic Society International Conference Meetings Abstracts American Thoracic Society International Conference Meetings Abstracts*; American Thoracic Society: New York, NY, USA, 2019; p. A5403.
101. Kaminski, N.; Belperio, J.A.; Bitterman, P.B.; Chen, L.; Chensue, S.W.; Choi, A.M.K.; Dacic, S.; Dauber, J.H.; Bois, R.M.; Enghild, J.J.; et al. Idiopathic Pulmonary Fibrosis. Proceedings of the 1st Annual Pittsburgh International Lung Conference. October 2002. *Am. J. Respir. Cell Mol. Biol.* **2003**, *29*, S1–S105. [[CrossRef](#)]
102. Grimminger, F.; Günther, A.; Vancheri, C. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. *Eur. Respir. J.* **2015**, *45*, 1426–1433. [[CrossRef](#)]
103. Pamuk, O.N.; Can, G.; Ayvaz, S.; Karaca, T.; Pamuk, G.E.; Demirtas, S.; Tsokos, G.C. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model. *Clin. Exp. Rheumatol.* **2015**, *33*, 15–22.
104. Poeck, H.; Ruland, J. SYK kinase signaling and the NLRP3 inflammasome in antifungal immunity. *J. Mol. Med.* **2010**, *88*, 745–752. [[CrossRef](#)] [[PubMed](#)]
105. Lin, Y.-C.; Huang, D.-Y.; Wang, J.-S.; Lin, Y.-L.; Hsieh, S.-L.; Huang, K.-C.; Lin, W.-W. Syk is involved in NLRP3 inflammasome-mediated caspase-1 activation through adaptor ASC phosphorylation and enhanced oligomerization. *J. Leukoc. Biol.* **2015**, *97*, 825–835. [[CrossRef](#)]
106. De Nardo, D.; De Nardo, C.M.; Latz, E. New insights into mechanisms controlling the NLRP3 inflammasome and its role in lung disease. *Am. J. Pathol.* **2014**, *184*, 42–54. [[CrossRef](#)] [[PubMed](#)]
107. Artlett, C.M. The Role of the NLRP3 Inflammasome in Fibrosis. *Open Rheumatol. J.* **2012**, *6*, 80–86. [[CrossRef](#)] [[PubMed](#)]
108. Anderson, E.C.; Wong, M.H. Caught in the Akt: Regulation of WNT signaling in the intestine. *Gastroenterology* **2010**, *139*, 718–722. [[CrossRef](#)] [[PubMed](#)]
109. Langhammer, T.-S.; Roolf, C.; Krohn, S.; Kretzschmar, C.; Huebner, R.; Rolfs, A.; Freund, M.; Junghanss, C. PI3K/Akt Signaling Interacts With Wnt/ β -Catenin Signaling But Does Not Induce An Accumulation Of β -Catenin In The Nucleus Of Acute Lymphoblastic Leukemia Cell Lines. *Blood* **2013**, *122*, 4886. [[CrossRef](#)]
110. Chen, Z.; Oh, S.Y.; Fang, P.; Li, Q.; Zhang, F.; Tang, H.; Homer, R.; Zhang, X.; Kaminski, N.; Zheng, T.; et al. Tyrosine Phosphatase SHP-1 Regulates Pulmonary Fibrosis Through Inhibition of β -Catenin Activation in Lung Epithelial Cells. In *Proceedings of the B107. MECHANISTIC ADVANCES IN PULMONARY FIBROSIS*; American Thoracic Society: New York, NY, USA, 2018; p. A4364.
111. Park, J.; Jeong, J.; Kim, Y.; Oh, S.; Oh, M.; Wu, F.; Zheng, T.; Zhu, Z. Increased Susceptibility to Bleomycin-Induced Pulmonary Injury and Fibrosis in Mice Deficient in Protein Tyrosine Phosphatase SHP-1. *J. Allergy Clin. Immunol.* **2009**, *123*, 729. [[CrossRef](#)]
112. Lam, A.P.; Gottardi, C.J. β -catenin signaling: A novel mediator of fibrosis and potential therapeutic target. *Curr. Opin. Rheumatol.* **2011**, *23*, 562–567. [[CrossRef](#)]
113. Piersma, B.; Bank, R.A.; Boersema, M. Signaling in fibrosis: TGF- β , WNT, and YAP/TAZ converge. *Front. Med.* **2015**, *2*, 59. [[CrossRef](#)]
114. Vallée, A.; Lecarpentier, Y.; Guillevin, R.; Vallée, J.N. Interactions between TGF- β 1, canonical WNT/ β -catenin pathway and PPAR γ in radiation-induced fibrosis. *Oncotarget* **2017**, *8*, 90579–90604. [[CrossRef](#)]

115. Wynn, T.A. Integrating mechanisms of pulmonary fibrosis. *J. Exp. Med.* **2011**, *208*, 1339–1350. [[CrossRef](#)] [[PubMed](#)]
116. Cao, H.; Wang, C.; Chen, X.; Hou, J.; Xiang, Z.; Shen, Y.; Han, X. Inhibition of Wnt/ β -catenin signaling suppresses myofibroblast differentiation of lung resident mesenchymal stem cells and pulmonary fibrosis. *Sci. Rep.* **2018**, *8*, 1–14. [[CrossRef](#)] [[PubMed](#)]
117. Kim, T.H.; Kim, S.H.; Seo, J.Y.; Chung, H.; Kwak, H.J.; Lee, S.K.; Yoon, H.J.; Shin, D.H.; Park, S.S.; Sohn, J.W. Blockade of the Wnt/ β -catenin pathway attenuates bleomycin-induced pulmonary fibrosis. *Tohoku J. Exp. Med.* **2011**, *223*, 45–54. [[CrossRef](#)] [[PubMed](#)]
118. Tzouvelekis, A.; Karamitsakos, T.; Min, K.; Xylourgidis, N.; Yu, G.; Herazo-Maya, J.; Bizenhofer, L.; Bennett, A.; Kaminski, N. Role of Mitogen activated-kinase (MAPK)-phosphatase (MKP)-5 in pulmonary fibrosis. *Eur. Respir. J.* **2018**, *52*, LSC-1111.
119. Madala, S.K.; Schmidt, S.; Davidson, C.; Ikegami, M.; Wert, S.; Hardie, W.D. MEK-ERK pathway modulation ameliorates pulmonary fibrosis associated with epidermal growth factor receptor activation. *Am. J. Respir. Cell Mol. Biol.* **2012**, *46*, 380–388. [[CrossRef](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).